TVTX CFO Cline sells 20,000 shares ($700.2K) at $35.01; retains 92,083 shares post-transaction.
Christopher R. Cline, CFO of Travere Therapeutics, sold 20,000 shares at $35.01, reducing his holdings from 112,083 to 92,083 shares. The transaction occurred at a price near the company's 52-week high of $36.47, with the stock currently at $34.85. Travere has demonstrated strong near-term momentum (90-day change: +64.8%) and meaningful revenue growth (+60.6% annually), though the company reported a full-year net loss despite recent quarterly profitability. The CFO's retention of 92.1K shares post-sale and the sale execution near recent highs provide limited direct insight into management confidence without additional context on vesting schedules or trading plan governance.